CVE:RVV Revive Therapeutics (RVV) Stock Price, News & Analysis C$0.08 +0.01 (+14.29%) As of 07/22/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Revive Therapeutics Stock (CVE:RVV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Revive Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.0852-Week RangeC$0.07▼C$0.25Volume212,852 shsAverage Volume93,085 shsMarket CapitalizationC$5.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada. Read More Receive RVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVV Stock News HeadlinesRevive Therapeutics Updates on Nerve Agent Countermeasure StudyAugust 19, 2025 | theglobeandmail.comRevive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt SettlementAugust 12, 2025 | finanznachrichten.deEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 26 at 2:00 AM | Timothy Sykes (Ad)Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study - MorningstarJuly 10, 2025 | morningstar.comM2025-07-08 | Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study | CSE:RVV | Press Release - StockhouseJuly 10, 2025 | stockhouse.comRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure StudyJuly 8, 2025 | financialpost.comF2025-06-26 | Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant ... - StockhouseJune 28, 2025 | stockhouse.comRevive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling OpportunityJune 26, 2025 | financialpost.comFSee More Headlines RVV Stock Analysis - Frequently Asked Questions How have RVV shares performed this year? Revive Therapeutics' stock was trading at C$0.08 at the beginning of 2025. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08. How do I buy shares of Revive Therapeutics? Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Revive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revive Therapeutics investors own include Aurora Cannabis (ACB), IntelGenx Technologies (IGXT), Vaxart (VXRT), Plug Power (PLUG), Sorrento Therapeutics (SRNE), Green Organic Dutchman (TGOD) and Zoom Communications (ZM). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:RVV CIKN/A Webwww.revivethera.com Phone+1-905-6055535FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow3.18 Book ValueC$0.02 per share Price / Book4.21Miscellaneous Outstanding Shares72,411,000Free FloatN/AMarket CapC$5.79 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (CVE:RVV) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Revive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.